2,6-Piperazinedione,4,4'-(1-methyl-1,2-ethanediyl)bis-, (S)- 2,6-Piperazinedione, 4,4'-propylenedi-,(+)- (8CI) (S)-(+)-1,2-Bis(3,5-dioxopiperazin-1-yl)propane
Dexrazoxane is hydrolysed by the enzyme dihydropyrimidine amidohydrolase in the liver and kidney to active metabolites that are capable of binding to metal ions.
It is excreted unchanged via the kidney
Potentially hazardous interactions with other drugs
Antiepileptics: may reduce absorption of fosphenytoin and phenytoin.
Ciclosporin: increased risk of immunosuppression with risk of lymphoproliferative disease.
Tacrolimus: increased risk of immunosuppression with risk of lymphoproliferative disease.
Vaccines: risk of generalised infections with live vaccines - avoid.
Dexrazoxane may be useful to attenuate the cardiotoxic effects of doxorubicin in patients who are showing signs of anthracycline cardiotoxicity, have cardiac disease, or are at maximum cumulative dosages of doxorubicin. It is also used to treat extravasation injuries associated with doxorubicin.
While dexrazoxane has been shown to be cardioprotective when given at dosages of 10 times the doxorubicin dose, there is evidence that it may also partially protect the cancer cells being treated.
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View